Regulation FD Disclosure (Form 8-K)

Item 7.01 Regulation FD.

In conjunction with its third quarter financial results announced yesterday, November 12, 2026, Nektar Therapeutics (the "Company") reported $952.9 million in cash and investments in marketable securities as of September 30, 2026. Consistent with its prior guidance, the Company expects that this cash balance will extend its cash runway into the third quarter of 2028 past the initial data readouts from the Phase 3 ZENITH AD trials in atopic dermatitis in the summer of 2028.

The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.